RecruitingPhase 2NCT05286814

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

Studying Adenocarcinoma of the liver and intrahepatic biliary tract

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Cancer Institute (NCI)
Principal Investigator: Jonathan M Hernandez, M.D.
National Cancer Institute (NCI)
Intervention: Dexamethasone(drug)
Enrollment: 70 enrolled
Eligibility: 18-120 years · All sexes
Timeline: 2022 – 2028

Study locations (1)

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05286814 on ClinicalTrials.gov

Other trials for Adenocarcinoma of the liver and intrahepatic biliary tract

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE2NCT04941287
Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
National Cancer Institute (NCI)

See all trials for Adenocarcinoma of the liver and intrahepatic biliary tract →

← Back to all trials